Noxa Antibody (69N15C9)
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-25251
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Validated:
Mouse
Predicted:
Rat (91%). Backed by our 100% Guarantee.
Applications
Western Blot
Label
Unconjugated
Antibody Source
Monoclonal Rat IgG2b Kappa Clone # 69N15C9
Concentration
0.5 mg/ml
Product Summary for Noxa Antibody (69N15C9)
Immunogen
This Noxa antibody (69N15C9) is made against amino acids 1-103 of mouse Noxa.
Clonality
Monoclonal
Host
Rat
Isotype
IgG2b Kappa
Theoretical MW
11.6 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Scientific Data Images for Noxa Antibody (69N15C9)
Western Blot: Noxa Antibody (69N15C9) [NBP2-25251]
Western Blot: Noxa Antibody (69N15C9) [NBP2-25251] - Western blot analysis of mouse A) Noxa recombinant protein, B) thymus and C) ovary using Noxa antibody at 1 ug/mL, 5 ug/mL and 5 ug/mL, respectively.Applications for Noxa Antibody (69N15C9)
Application
Recommended Usage
Western Blot
5 - 10 ug/mL
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein G purified
Formulation
PBS, 0.05% BSA
Preservative
0.05% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: Noxa
Noxa mediated apoptosis may follow its transcriptional activation by p53 as part of the DNA damage response. However, Noxa expression may be induced by HIF-1 alpha under hypoxia, promoting apoptosis independently of p53 (1). Inhibition of the anti-apoptotic Bcl2 family member Myeloid cell leukemia-1 (Mcl-1) by Noxa, leads to the activation of pro-apoptotic Bcl2 homologous antagonist killer (Bak) and Bcl2 associated X (Bax) proteins, and apoptosis through the intrinsic mitochondrial pathway (2). Other BH3 only proteins such as Bim, Puma, Bad and Bid act via the same mechanism, targeting Mcl-1 and inducing Bak/Bax mediated mitochondrial outer membrane permeabilization (MOMP), cytochrome c release and caspase 9 activation (3). Overexpression of antiapoptotic Bcl2 family members is common in various types of cancer including prostate cancer. A recent study identified antiapoptotic Bcl2 proteins involved in the development of resistance towards the androgen receptor antagonist enzalutamide, which is used for the treatment of metastatic castration-resistant prostate cancer (mCRPC) (3).
References
1.Ploner, C., Kofler, R., & Villunger, A. (2008). Noxa: At the tip of the balance between life and death. Oncogene. https://doi.org/10.1038/onc.2009.46
2.Xiang, W., Yang, C. Y., & Bai, L. (2018). MCL-1 inhibition in cancer treatment. OncoTargets and Therapy. https://doi.org/10.2147/OTT.S146228
3.Pilling, A. B., & Hwang, C. (2019). Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide. Prostate. https://doi.org/10.1002/pros.23843
Alternate Names
adult T cell leukemia-derived PMA-responsive, APR, Immediate-early-response protein APR, NOXAPMA-induced protein 1, phorbol-12-myristate-13-acetate-induced protein 1, PMA-Induced Protein 1, Protein Noxa
Gene Symbol
PMAIP1
UniProt
Additional Noxa Products
Product Documents for Noxa Antibody (69N15C9)
Product Specific Notices for Noxa Antibody (69N15C9)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...